Dr David Stamler – CEO – Alterity Therapeutics Limited (ASX:ATH) is developing first-in-class therapies to treat neurodegenerative disease. The company’s lead drug candidate, ATH434, has demonstrated efficacy in several animal models of Parkinsonian disorders and is being evaluated in clinical trials.
Alterity Therapeutics (ASX:ATH) – Webinar Presentation
